EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Final
Results
Cytos Biotechnology Ltd announces full year 2011 financial results

17.02.2012 / 07:00

Schlieren (Zurich), Switzerland, February 17, 2012 - Cytos Biotechnology
Ltd (SIX:CYTN) today presented its full year 2011 financial results.

The complete press release as well as the Annual Report 2011 can be
downloaded on Cytos Biotechnology´s website (www.cytos.com).

For further information please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel.: +41 44 733 46 46
e-Mail: harry.welten@cytos.com
Website: http://www.cytos.com

About Cytos Biotechnology Ltd
Cytos Biotechnology Ltd is a Swiss public biotechnology company that
specializes in the development and commercialization of a new class of
biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM) are
intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient´s immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. The Immunodrug(TM) candidates are developed both in-house and
together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as
a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich,
the Company is located in Schlieren (Zurich). Cytos Biotechnology Ltd is
listed on the main segment at the SIX Swiss Exchange (SIX:´CYTN´).

End of Corporate News

17.02.2012 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1´300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten

Language:                 English                                     
Company:                  Cytos Biotechnology AG                      
                          Wagistr. 25                                 
                          8952 Schlieren                              
                          Switzerland                                 
Phone:                    +41 44 733 4747                             
Fax:                      +41 44 733 4740                             
E-mail:                   info@cytos.com                              
Internet:                 www.cytos.com                               
ISIN:                     CH0011025217, CH0029060735                  
Swiss Security Number:    -                                           
Listed:                   Freiverkehr in Berlin, München, Stuttgart;  
                          Open Market in Frankfurt; SIX               

End of News    EquityStory AG News-Service  

  
157148 17.02.2012                                                      

Excerpt from:
DGAP-News: Cytos Biotechnology Ltd announces full year 2011 financial results